Vosyn Unveils AI Advancements at Collision Conference, Announces $8MM Round
After successfully completing a $2MM pre-seed round, Vosyn has launched an $8MM seed round, with
Demand for AI is rapidly increasing at a compound annual growth rate (CAGR) of 42.2% from 2020 to 2027, and with 72% of consumers preferring products in their native language, effective multilingual communication is critically important. Vosyn is strategically positioned to meet this demand with groundbreaking solutions.
VosynVerse, the world's most powerful content consumption engine, is leading this revolution. Vosyn's multilingual, contextual AI foundation model provides real-time, accurate translations across video, audio, text, and applications. This delivers seamless access to global content and offers a richer, more meaningful experience for people worldwide. Through API integration, businesses can ensure their communications and interactions are understood in any language, enhancing global reach and effectiveness.
Committed to breaking language barriers and aligning with ESG/SDG guidelines to enhance the standards of Responsible AI, Vosyn's technology fosters global communication and understanding, driving positive social impact by making content accessible to all, regardless of language. Vosyn invites social impact investors to join them in their mission to create a more inclusive and connected world.
Join Vosyn at the Collision Conference, where they will highlight their latest AI innovations and strategic growth plans. Attendees can visit Vosyn at Booth B214 on
- Visit Vosyn at Booth B214
- Media can connect for exclusive insights.
- Explore investment opportunities
Collision Conference
Collision Mixer
Investor Link
www.vosyn.ai
View original content:https://www.prnewswire.com/news-releases/vosyn-unveils-ai-advancements-at-collision-conference-announces-8mm-round-302174671.html
SOURCE Vosyn Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- When an autism diagnosis changes everything, 'The Healing Way' shows parents a new path forward
- OPENLANE Announces Pricing of Secondary Offering of Common Stock, Including Concurrent Share Repurchase
- New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share